ONO-4538 Phase II Rollover Study (ONO-4538-98)
A Multicenter, Open-label, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 as Monotherapy or in Combination With Other Therapies and Are Continuing ONO-4538 Treatment (ONO-4538-98)
Ono Pharmaceutical Co., Ltd.
59 participants
Sep 10, 2020
INTERVENTIONAL
Conditions
Summary
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV infusion over 30 minutes
IV infusion over 2 hours
Administered orally twice daily
Administered orally twice daily
IV infusion over 30 minutes
Administered orally once daily for 5 days every 28 days
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04566380